U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT07491913) titled 'Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission' on March 16.
Brief Summary: Takayasu arteritis is a chronic large-vessel vasculitis affecting the aorta and its major branches. Biologic therapies such as tumor necrosis factor inhibitors and tocilizumab are commonly used in patients with refractory or relapsing disease. However, there is limited evidence regarding the optimal duration of biologic therapy and the safety of treatment discontinuation in patients who achieve sustained remission.
This prospective study aims to evaluate the outcomes of planned biologic treatment withdrawal in patients ...